EyePoint, Inc. has dosed the first patients in both Phase 3 COMO and CAPRI global clinical trials of DURAVYU (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME). DURAVYU is an investigational sustained delivery therapy that delivers vorolanib, a selective tyrosine kinase inhibitor (TKI) with a multi-mechanism of action, inhibiting VEGF-mediated vascular permeability, PDGF, and IL-6 mediated inflammation. The DME Phase 3 program consists of two global, randomized, double-masked, aflibercept controlled non-inferiority trials (COMO and CAPRI), each enrolling approximately 240 patients. Patients in the DURAVYU 2.7mg arm will be re-dosed every six months via a single standard intravitreal injection. The primary endpoint for these trials is a non-inferior change from baseline in best corrected visual acuity (BCVA) to weeks 52 and 56, blended versus aflibercept control. Topline data for DURAVYU in DME is anticipated in the second half of 2027. The company's Phase 3 trials for wet age-related macular degeneration (wet AMD), LUGANO and LUCIA, are fully enrolled, with topline data expected beginning in mid-2026. EyePoint has approximately $300 million in cash and investments, which is expected to support its operating runway into Q4 2027.